Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity : Targeting the Microenvironment in Hematological Malignancies: How to Condition both Stromal and Effector Cells to Overcome Cancer SpreadingKRUSCH, M; SALIH, H. R.Current medicinal chemistry. 2011, Vol 18, Num 34, pp 5174-5184, issn 0929-8673, 11 p.Article

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responsesMETZELDER, S. K; SCHROEDER, T; HEINICKE, T et al.Leukemia. 2012, Vol 26, Num 11, pp 2353-2359, issn 0887-6924, 7 p.Article

4-1BB ligand: just another costimulating molecule?SALIH, H. R; KIENER, P. A; NÜSSLER, V et al.International journal of clinical pharmacology and therapeutics. 2002, Vol 40, Num 8, pp 348-353, issn 0946-1965, 6 p.Conference Paper

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic LeukemiaLO-COCO, F; AVVISATI, G; SPECCHIA, G et al.The New England journal of medicine. 2013, Vol 369, Num 2, pp 111-121, issn 0028-4793, 11 p.Article

Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL)BUECHELE, C; BAESSLER, T; WIRTHS, S et al.Leukemia. 2012, Vol 26, Num 5, pp 991-1000, issn 0887-6924, 10 p.Article

Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemiaHOFMANN, M; GROSSE-HOVEST, L; RAMMENSEE, H.-G et al.Leukemia. 2012, Vol 26, Num 6, pp 1228-1237, issn 0887-6924, 10 p.Article